History and key figures


PHARMASYS was created in 2005 by Jerome Larfi with the idea – which was also shared with the FDA – that the methods of the market players were inefficient and obsoletes.

Since the beginning, PHARMASYS has established itself in new practices in terms of compliance GxP based on the Risk Analysis approach as it was impulsed by the FDA at the end of 2003. The FDA « cGMP’s for the 21th century » method generated a whole new frame of guidelines and methods :

  • Data Integrity GMP guidances : FDA, MHRA, PIC’s, WHO
  • Annexe 11 GMP, 2011
  • FDA 21 CFR Part 11 guidance 2003  
  • GAMP 5, 2008 & ASTM E 2500
  • ICH Q9 Risk Analysis

Thanks to the relevance of its interventions in consulting, audit and training,  PHARMASYS has since known a rapid development that continues unabated :

in 2008

PHARMASYS settled in Lyon

in 2009

PHARMASYS settled in Toulouse

in 2012

PHARMASYS settled in Switzerland through its subsidiary PHARMASYS CH and in Belgium

in 2013

PHARMASYS partnered with Polarion Life Sciences editor and proposes to his clients the Polarion Life Sciences solution for requirements traceability

in 2018

PHARMASYS elected to TOP500 of fastest growing French companies

in 2019

PHARMASYS (again) elected to TOP500 of fastest growing French companies


  • A European leader in consulting for GxP digital: data integrity, quality and compliance.
  • Dozens of employees capitalizing on unique expertise to support our clients Pharma, DM for their digital transformation.
  • More than 75 references – from larger groups to smaller companies.


As part of our development, we are strengthening our teams.

Follow us
on LinkedIn


36, Place Nelson Mandela
91300 MASSY
Tel : +33 (0)1 69 35 05 43
Contact us